“The drug gives you your life back.”
An eczema patient in a Mount Sinai clinical trial and a Mount Sinai physician-scientist who led the trial discuss Dupixent® (dupilumab), the first biologic medicine approved by the U.S. Food and Drug Administration for the treatment of adults with moderate to severe atopic dermatitis.
Austin Jacobson, Eczema Patient, Mount Sinai Clinical Trial:
“Living with eczema is hell. It’s like having poison ivy from head to toe. It doesn’t ever go away. You can’t sleep because you’re itching so badly. You can’t concentrate because all you think about is itch. Wearing clothes is painful, the showers were terrible. It affects every single aspect of your life.”
“Dupilumab works. The other remedies that I tried worked for a short term, and then they stopped working, and then they were useless. The drug gives you your life back. You do all the things that you used to do before you had this condition. It’s like you never had it.”
“Dupilumab really is a game changer.”
Emma Guttman-Yassky, MD, PhD, Vice Chair of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York, a principal investigator in a clinical trial of the new drug:
“In the United States we have 30 million with eczema. These patients usually will have multiple treatments and, despite the treatment, still have horrible disease. Some of the treatments, some of the immunosuppressants, are effective. But these drugs have terrible side effects. We hope that for these patients we can put them on a safe drug that basically will provide them clear skin. Patients are following this because for so long they didn’t have anything.”
“The bottom line is that dupilumab really is a game changer. It not only provides the efficacy similar to the immunosuppressants, but also it is safe to be given long term, and that’s why it’s a game changer in the world of eczema.”